Survivin Expression as a Predictive Marker for Local Control in Patients With High-Risk T1 Bladder Cancer Treated With Transurethral Resection and Radiochemotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 74, Issue 5, 2009, Pages 1455-1460

  Weiss, Christian ^a   von Römer, Felix ^a   Capalbo, Gianni ^a   Ott, Oliver J ^b   Wittlinger, Michael ^b   Krause, Steffen F ^b   Sauer, Rolf ^b   Rödel, Claus ^a   Rödel, Franz ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

High risk T1 bladder cancer; Organ preservation; Radiochemotherapy; Survivin

Indexed keywords

BLADDER CANCERS; CLINICAL OUTCOME; DISEASE-SPECIFIC SURVIVALS; HIGH-RISK T1 BLADDER CANCER; IMMUNOHISTOCHEMISTRY; IN-SITU; LOCAL CONTROL; LOCAL FAILURE; ORGAN PRESERVATION; PROTEIN EXPRESSIONS; RADIOCHEMOTHERAPY; SURVIVIN; TRANSURETHRAL RESECTIONS; TUMOR PROGRESSIONS; TUMOR SAMPLES; UROTHELIAL CANCER; UROTHELIUM;

TUMORS;

RISKS;

CARBOPLATIN; CISPLATIN; FLUOROURACIL; SURVIVIN;

AGED; ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIATION DOSE; TRANSURETHRAL RESECTION; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR RECURRENCE; UROGENITAL TRACT CANCER;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA IN SITU; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY DOSAGE; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 67651112126     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.10.063     Document Type: Article

References (40)

1. Manoharan M., and Soloway M.S. Optimal management of the T1G3 bladder cancer. Urol Clin North Am 32 (2005) 133-145
2. Smith Jr. J.A., Labasky R.F., Cockett A.T., et al. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 162 (1999) 1697-1701
3. Amling C.L., Thrasher J.B., Frazier H.A., et al. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 151 (1994) 31-35 discussion 35-36
4. Denzinger S., Fritsche H.M., Otto W., et al. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: Do risk factors define feasibility of bladder-sparing approach?. Eur Urol 53 (2008) 146-152
5. Freeman J.A., Esrig D., Stein J.P., et al. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 76 (1995) 833-839
6. Malkowicz S.B., Nichols P., Lieskovsky G., et al. The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2). J Urol 144 (1990) 641-645
7. Stockle M., Alken P., Engelmann U., et al. Radical cystectomy-often too late?. Eur Urol 13 (1987) 361-367
8. Weiss C., Wolze C., Engehausen D.G., et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: An alternative to intravesical therapy or early cystectomy?. J Clin Oncol 24 (2006) 2318-2324
9. Weiss C., Rodel F., Wolf I., et al. Combined-modality treatment and organ preservation in bladder cancer: Do molecular markers predict outcome?. Strahlenther Onkol 181 (2005) 213-222
10. Chyle V., Pollack A., Czerniak B., et al. Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 35 (1996) 281-287
11. Harada S., Sato R., Nakamura R., et al. The correlation between spontaneous and radiation-induced apoptosis in T3B bladder cancer (histological grade G3), and the precedence between the two kinds of apoptosis for predicting clinical prognosis. Int J Radiat Oncol Biol Phys 48 (2000) 1059-1067
12. Moonen L., Ong F., Gallee M., et al. Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 49 (2001) 1305-1310
13. Rodel C., Grabenbauer G.G., Rodel F., et al. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: Possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys 46 (2000) 1213-1221
14. Ambrosini G., Adida C., Sirugo G., et al. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 273 (1998) 11177-11182
15. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3 (1997) 917-921
16. Altieri D.C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22 (2003) 8581-8589
17. Schultz I.J., Witjes J.A., Swinkels D.W., et al. Bladder cancer diagnosis and recurrence prognosis: Comparison of markers with emphasis on survivin. Clin Chim Acta 368 (2006) 20-32
18. Rodel F., Hoffmann J., Distel L., et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 65 (2005) 4881-4887
19. Tanaka K., Iwamoto S., Gon G., et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6 (2000) 127-134
20. Kappler M., Kotzsch M., Bartel F., et al. Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clin Cancer Res 9 (2003) 1098-1104
21. Rodel C., Grabenbauer G.G., Kuhn R., et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 20 (2002) 3061-3071
22. Gonzalez S., Aubert S., Kerdraon O., et al. Prognostic value of combined p53 and survivin in pT1G3 urothelial carcinoma of the bladder. Am J Clin Pathol 129 (2008) 232-237
23. Ku J.H., Kwak C., Lee H.S., et al. Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol 171 (2004) 631-635
24. Smith S.D., Wheeler M.A., Plescia J., et al. Urine detection of survivin and diagnosis of bladder cancer. J Am Med Assoc 285 (2001) 324-328
25. Weikert S., Christoph F., Schrader M., et al. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 116 (2005) 100-104
26. Kenney D.M., Geschwindt R.D., Kary M.R., et al. Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary survivin. Tumour Biol 28 (2007) 57-62
27. Moussa O., Abol-Enein H., Bissada N.K., et al. Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer. J Urol 175 (2006) 2312-2316
28. Shariat S.F., Casella R., Khoddami S.M., et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 171 (2004) 626-630
29. Swana H.S., Grossman D., Anthony J.N., et al. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 341 (1999) 452-453
30. Yin W., Chen N., Zhang Y., et al. Survivin nuclear labeling index: A superior biomarker in superficial urothelial carcinoma of human urinary bladder. Mod Pathol 19 (2006) 1487-1497
31. Karam J.A., Lotan Y., Ashfaq R., et al. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology 70 (2007) 482-486
32. Gazzaniga P., Gradilone A., Giuliani L., et al. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 14 (2003) 85-90
33. Shariat S.F., Ashfaq R., Karakiewicz P.I., et al. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 109 (2007) 1106-1113
34. Als A.B., Dyrskjot L., von der Maase H., et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 13 (2007) 4407-4414
35. Capalbo G., Rodel C., Stauber R.H., et al. The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target. Strahlenther Onkol 183 (2007) 593-599
36. Stauber R.H., Mann W., and Knauer S.K. Nuclear and cytoplasmic survivin: Molecular mechanism, prognostic, and therapeutic potential. Cancer Res 67 (2007) 5999-6002
37. Pennati M., Binda M., Colella G., et al. Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol 120 (2003) 648-654
38. Hou J.Q., He J., Wang X.L., et al. Effect of small interfering RNA targeting survivin gene on biological behaviour of bladder cancer. Chin Med J (Engl) 119 (2006) 1734-1739
39. Kunze D., Wuttig D., Kausch I., et al. Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo. Int J Oncol 32 (2008) 1049-1056
40. Fuessel S., Kueppers B., Ning S., et al. Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells. J Urol 171 (2004) 2471-2476